ADHD, Predominantly Inattentive TypePhase 2NCT02189772
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
A Phase 2 study testing Metadoxine extended release in people with ADHD, Predominantly Inattentive Type, run by Alcobra Ltd. at 6 sites in Israel.
Trial summary
The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly inattentive symptoms. Read more about this study
- Who is it for?
- Ages 13 to 17 years
- Conditions the study is for
- ADHD, Predominantly Inattentive Type
- What is being tested?
- Metadoxine extended release
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 83 participants
- Where
- 6 sitesIsrael
- Study dates
- Aug 2014to Jan 2015
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Adolescent males and females, 13-17 years old, inclusive, at screening visit, with visible axillary hair.
- Diagnosed with predominantly inattentive ADHD based on DSM V criteria for ADHD as assessed by the Adolescent ADHD Clinician Diagnostic Scale (Adol-CDS V1.2).
- Clinical severity of at least a moderate level (Clinical Global Impression-Severity score of 4 or above).
- STAI State score of <52, STAI Trait score of <52 and BDI score of <19.
- Sexually active subjects of childbearing potential must agree to use an effective contraceptive throughout the study (e.g., oral contraceptives or Norplant®; a reliable double barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; vasectomy; or abstinence) and for at least a month after the study, and must have a negative serum pregnancy test at the Screening Visit. Females of childbearing potential are defined as women who are between menarche and 2 years post-menopause and who are not surgically sterilized. Males and Female subjects who are not sexually active, and who agree to be abstinent throughout the study, will not be required to use birth control.
- Subject is able to attend the clinic regularly and reliably.
Show all 11Show fewer
- Subject is able to swallow tablets and capsules.
- Able to understand, read, write and speak Hebrew fluently to complete study related materials.
- Parents or legal authorized guardians (LAR), and subject, able to understand and sign written informed consent/assent to participate in the study
- Subject and parents/LARs provide assent/consent to participate in the study. per applicable laws and regulations
- Subject weighs ≥40 kg or ≤100 kg
Who cannot join
- Subject has any psychiatric condition (e.g., schizophrenia or personality disorder as diagnosed by DSM-V) or clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by the investigator using medical history, physical examination, neurological examination, laboratory tests, and electrocardiograms. Common diseases such as mild hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C <6.5%), etc, are allowed per the investigator's judgment as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks before randomization and subsequently throughout the study. If there are any concerns about the suitability of the subject's medical or surgical condition, the investigator should review the subject's history with the medical monitor.
- Subject has a known or suspected human immune deficiency virus positive status or has diseases such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
- Subject has a history of an allergy or sensitivity to B-complex vitamins.
- Subject has a history of intellectual disability or a history or suspicion of autism spectrum disorder.
- Subject has a current clinically significant Axis I diagnosis (other than ADHD) according to the K-SADS-PL or has a lifetime history of bipolar disorder or psychosis.
- Subject has used mega-dose vitamin B6/pyridoxine during the 28 days before the Randomization Visit. Subjects will be allowed to have a 28-day washout of mega-dose vitamin B6/pyridoxine after the Screening visit. Routine multivitamin supplements will be allowed.
Show all 18Show fewer
- Subject has used high-dose supplements of omega-3 fatty acids ≥ 500 mg on at least 1 day (such as softgels, capsules, or fish oils; regular daily dietary consumption of fish is allowed) or folic acid supplements (other than routine multivitamin supplements) during the 2 weeks before the Randomization Visit.
- Subject has used an investigational medication/treatment in the 30 days before the Screening Visit
- Subject has used any medication or food supplement that the investigator or the medical monitor considers unacceptable during the 14-day period before randomization. This includes, but is not limited to, sympathomimetic agents, clonidine, guanfacine, norepinephrine reuptake inhibitors, serotonin reuptake inhibitors, sedative-hypnotics, benzodiazepines, sedating antihistamines, herbal preparations that would confound safety or efficacy assessments, and narcotics. Questions regarding the acceptability of medications and food supplements (such as melatonin) will be discussed with the medical monitor before study entry.
- Subject has a current drug or alcohol dependence or substance abuse disorder according to DSM-V Text Revision criteria (excluding nicotine) or a history of such dependence within the last 6 months. Subject should also agree to keep their caffeine intake consistent and refrain from consuming ≥300 mg per day of caffeine (no more than three 8-ounce servings of coffee) during the study.
- Subject has suicidality, defined as active ideation, an intent or plan, or any significant lifetime suicidal behavior (actual attempt, aborted attempt, interrupted attempt, or act or preparation towards imminently making a suicide attempt). Subjects exhibiting history (within previous 12 months) of non-suicidal self-injurious behavior will be excluded.
- Subject has taken any prescription or non-prescription ADHD medications during the 14 days before the randomization visit or 28 days in the case of atomoxetine..
- Subject is significantly visually impaired to an extent that is not able to be corrected by prescription glasses or contact lenses
- Subject is closely related to the sponsor, investigator, or study staff. Eligibility of subjects with any relationship to the sponsor, investigator, or study staff will be discussed with the medical monitor before study entry.
- Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity as judged by the investigator.
- Subject cannot fully comprehend the implications of the protocol, cannot comply with its requirements, or is incapable of following the study schedule for any reason.
- Subject is pregnant, lactating, or using an inadequate contraceptive method.
- Subject is not currently participating in other clinical trials.
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
Israel6 sites
Rambam Medical Center
Haifa, Israel
Shalvata Mental Health Center
Hod HaSharon
Hadassah-Hebrew University Medical Center,
Jerusalem, Israel
Geha Medical Centre
Petah Tikva, Israel
The Chaim Sheba medical center, Tel Hashomer
Ramat Gan, Israel
Assaf Harofeh MC
Zrifin, Israel
About this study
Official title: Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly inattentive symptoms. The study will also try to evaluate the efficacy of MDX and its level in the blood.
Read the detailed description
This will be a randomized, double-blind, placebo-controlled multi-center, fixed dose, single dose study in adolescent subjects with PI-ADHD. Eligible subjects will be randomized in a 1:1 ratio to receive single administration of either MDX (approximately 14-22 mg/kg) or matching placebo.
Subjects taking a course of methylphenidate, amphetamine or atomoxetine at least two weeks prior to screening will require a 2-week wash-out (for methylphenidate, amphetamine) or a 4-week wash-out (for atomoxetine) and be requested to attend an interim screening visit.
The study will consist of three periods: a screening period of up to three weeks (and five in the case of atomoxetine washout), a 1 day treatment period, and a one-week safety follow-up period.
Overview of Study Visits Screening Period - Visit 1 (Screening/Baseline) Following signing of informed consent/assent, subjects will be screened for study eligibility. Each subject will undergo a battery of evaluations with various rating scales including Adolescent ADHD Clinical Diagnostic Scale1 (ACDS v1.2), Kiddie - Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL), Columbia-Suicide Severity rating scale (C-SSRS), State Trait Anxiety Inventory (STAI-A and STAI-T), Beck Depression Inventory (BDI), CGI-S (Clinical Global Impression - Severity), Time-Sensitive ADHD Symptom Scale (TASS), Wechsler Intelligence Scale for Children- fourth edition (WISC-IV) sub-tests2 and Test of Variables of Attention (TOVA)3. Eligible subjects who did not require a wash-out, will be eligible for the study. In addition, the following standard assessments will be performed: assessment of inclusion/exclusion, collection of demographic data, medical history, prior medications, neurological exam, neuropathy questionnaire, physical exam, height and weight, vital signs, ECG, laboratory evaluations including hematology (complete blood count, CBC), chemistry, plasma concentration of metadoxine, urinalysis, and serum pregnancy test for women of child bearing potential. The screening visit may be conducted over multiple days. Screening visit data will be considered baseline data for statistical analysis purposes for subject requiring no washout.
Visit 1a (Interim screening visit) This visit is applicable to subjects taking medications or supplements requiring washout such as methylphenidate, amphetamine or atomoxetine at any time during the 2 weeks preceding Visit 1 (screening); these subjects will undergo a 2-week washout (for cases such as methylphenidate or amphetamine treatment) or a 4-week washout (for cases such as atomoxetine treatment) period after which they will attend an interim screening visit. Baseline TOVA, WISC-IV sub-tests1, and TASS will be performed at Visit 1a. In addition, the C-SSRS, adverse events, and concomitant medications will be recorded at this visit.
Treatment Period - Visit 2 (Day 1, visit window + 3 days) At study visit 2 (Day 1), each eligible subject will be randomized in a 1:1 allocation to receive either MG01CI or matching placebo; dose will be determined by weight at screening visit 1. Investigational product will be administered at the clinic. The WISC-IV sub-tests of Digit Span, Coding, Letter Number Sequencing, and Symbol Search will be administered. Subjects will undergo evaluations with the TOVA test 3 to 5 hours post-dose to assess their response to treatment. In addition, subjects will complete the TASS prior to administration of study drug, and 3-5 hours post-dose. At this visit, the subjects will also undergo safety assessments including urine pregnancy test (pre-dose), vital signs , neurological exam, neuropathy questionnaire, the C-SSRS and recording of adverse events (AEs) and concomitant medications. Subjects will have blood drawn for plasma concentrations of metadoxine at 1-2 hours post-dose and 3-4 hours post-dose.
Follow-Up Period - Visit 3 (Day 8, visit window ± 3 days) One week after the end of treatment, subjects will complete the TASS and will undergo safety assessments including physical exam, neurological exam, neuropathy questionnaire, vital signs, ECG, laboratory evaluations (hematology, chemistry, and urinalysis including urine pregnancy test for women of child bearing potential), the C-SSRS, and documentation of concomitant medications and AEs, if any.
- Conditions
- ADHD, Predominantly Inattentive Type
- Being tested
- Metadoxine extended release, Placebo
- Keywords
- ADHD, Inattention, MDX
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Metadoxine extended releaseDrug
Also called MDX
MG01CI
PlaceboDrug
Also called Sugar pill
Inactive drug
| Study group | Role | What they receive |
|---|---|---|
| MDX (metadoxine extended release) | Experimental | Route of administration: oral
The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:
* 40-49 kg 700 mg consisting of a 700 mg tablet
* 50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet
* 65-100 kg 1400 mg consisting of two 700 mg tablets Receives: Drug: Metadoxine extended release |
| placebo | Placebo comparator | Placebo tablets will be similar in appearance (color and size) to the investigational product Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability
Frequency of treatment emergent adverse events (AEs). Frequency of subjects who withdrew early from the study due to AE.
Measured: Up to 6 weeks
Secondary outcomes (2)
Efficacy
Change in TOVA 8 API from Baseline to 3-5 hours post-dose for all subjects and for subjects who have an abnormal TOVA 8 API at baseline (score <0). Change in TOVA sub-scores1 from Baseline to 3 -5 hours post-dose for all subjects and for subjects who have an abnormal TOVA 8 API at baseline (score<0).
TOVA Response Rates: Change in TOVA 8 API from abnormal (ADHD score below zero, sub-scores below 85) to normal value post-dose. Improvement of 0.8 points in TOVA 8 API or 8 points in any sub-score for all subjects and for those subjects who have an abnormal TOVA 8 API at baseline (score<0).
Change in each of WISC-IV subtests (Digit Span, Coding, Letter Number Sequencing, and Symbol Search) from Baseline to post-dose. Change in Working memory and Processing Speed from Baseline (derived from subtests)
Measured: Up to 5 weeks
PK
Blood samples for baseline plasma concentration of metadoxine will be collected at Screening. On study visit 2 (Day 1), subjects will have another PK blood sample at 1-2 hours and 3-4 hours post-dose. The PK samples will be sent to the bioanalysis laboratory for assay.
Measured: Up to 5 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2014 (estimated)
- Study startAug 2014
- Primary completionJan 2015
- Study completionJan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ADHD, Predominantly Inattentive TypeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 83 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alcobra Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Iris Manor, MD, Principal investigator, ADHD Unit, Geha Medical Center, Petah Tikva, Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02189772
- Sponsor's protocol ID
- AL015
- Status last verified
- Dec 2014
- First submitted
- 11 Jul 2014
- Last updated
- 4 Mar 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
- ClinicalTrials.gov ID
- NCT02189772
- Acronym / sponsor ID
- AL015
- Conditions
- ADHD, Predominantly Inattentive Type
- Keywords
- ADHD, Inattention, MDX
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 83 participants (actual)
- Lead sponsor
- Alcobra Ltd.Industry (pharma, biotech, devices)
- Study start
- Aug 2014
- Primary completion
- Jan 2015 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 15 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly inattentive symptoms. The study will also try to evaluate the efficacy of MDX and its level in the blood.
Detailed description
This will be a randomized, double-blind, placebo-controlled multi-center, fixed dose, single dose study in adolescent subjects with PI-ADHD. Eligible subjects will be randomized in a 1:1 ratio to receive single administration of either MDX (approximately 14-22 mg/kg) or matching placebo.
Subjects taking a course of methylphenidate, amphetamine or atomoxetine at least two weeks prior to screening will require a 2-week wash-out (for methylphenidate, amphetamine) or a 4-week wash-out (for atomoxetine) and be requested to attend an interim screening visit.
The study will consist of three periods: a screening period of up to three weeks (and five in the case of atomoxetine washout), a 1 day treatment period, and a one-week safety follow-up period.
Overview of Study Visits Screening Period - Visit 1 (Screening/Baseline) Following signing of informed consent/assent, subjects will be screened for study eligibility. Each subject will undergo a battery of evaluations with various rating scales including Adolescent ADHD Clinical Diagnostic Scale1 (ACDS v1.2), Kiddie - Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL), Columbia-Suicide Severity rating scale (C-SSRS), State Trait Anxiety Inventory (STAI-A and STAI-T), Beck Depression Inventory (BDI), CGI-S (Clinical Global Impression - Severity), Time-Sensitive ADHD Symptom Scale (TASS), Wechsler Intelligence Scale for Children- fourth edition (WISC-IV) sub-tests2 and Test of Variables of Attention (TOVA)3. Eligible subjects who did not require a wash-out, will be eligible for the study. In addition, the following standard assessments will be performed: assessment of inclusion/exclusion, collection of demographic data, medical history, prior medications, neurological exam, neuropathy questionnaire, physical exam, height and weight, vital signs, ECG, laboratory evaluations including hematology (complete blood count, CBC), chemistry, plasma concentration of metadoxine, urinalysis, and serum pregnancy test for women of child bearing potential. The screening visit may be conducted over multiple days. Screening visit data will be considered baseline data for statistical analysis purposes for subject requiring no washout.
Visit 1a (Interim screening visit) This visit is applicable to subjects taking medications or supplements requiring washout such as methylphenidate, amphetamine or atomoxetine at any time during the 2 weeks preceding Visit 1 (screening); these subjects will undergo a 2-week washout (for cases such as methylphenidate or amphetamine treatment) or a 4-week washout (for cases such as atomoxetine treatment) period after which they will attend an interim screening visit. Baseline TOVA, WISC-IV sub-tests1, and TASS will be performed at Visit 1a. In addition, the C-SSRS, adverse events, and concomitant medications will be recorded at this visit.
Treatment Period - Visit 2 (Day 1, visit window + 3 days) At study visit 2 (Day 1), each eligible subject will be randomized in a 1:1 allocation to receive either MG01CI or matching placebo; dose will be determined by weight at screening visit 1. Investigational product will be administered at the clinic. The WISC-IV sub-tests of Digit Span, Coding, Letter Number Sequencing, and Symbol Search will be administered. Subjects will undergo evaluations with the TOVA test 3 to 5 hours post-dose to assess their response to treatment. In addition, subjects will complete the TASS prior to administration of study drug, and 3-5 hours post-dose. At this visit, the subjects will also undergo safety assessments including urine pregnancy test (pre-dose), vital signs , neurological exam, neuropathy questionnaire, the C-SSRS and recording of adverse events (AEs) and concomitant medications. Subjects will have blood drawn for plasma concentrations of metadoxine at 1-2 hours post-dose and 3-4 hours post-dose.
Follow-Up Period - Visit 3 (Day 8, visit window ± 3 days) One week after the end of treatment, subjects will complete the TASS and will undergo safety assessments including physical exam, neurological exam, neuropathy questionnaire, vital signs, ECG, laboratory evaluations (hematology, chemistry, and urinalysis including urine pregnancy test for women of child bearing potential), the C-SSRS, and documentation of concomitant medications and AEs, if any.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MDX (metadoxine extended release) | Experimental | Drug: Metadoxine extended releaseRoute of administration: oral The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows: * 40-49 kg 700 mg consisting of a 700 mg tablet * 50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet * 65-100 kg 1400 mg consisting of two 700 mg tablets |
| placebo | Placebo comparator | Drug: PlaceboPlacebo tablets will be similar in appearance (color and size) to the investigational product |
Who may qualify
- Ages
- 13 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (11 listed)
- Adolescent males and females, 13-17 years old, inclusive, at screening visit, with visible axillary hair.
- Diagnosed with predominantly inattentive ADHD based on DSM V criteria for ADHD as assessed by the Adolescent ADHD Clinician Diagnostic Scale (Adol-CDS V1.2).
- Clinical severity of at least a moderate level (Clinical Global Impression-Severity score of 4 or above).
- STAI State score of <52, STAI Trait score of <52 and BDI score of <19.
- Sexually active subjects of childbearing potential must agree to use an effective contraceptive throughout the study (e.g., oral contraceptives or Norplant®; a reliable double barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; vasectomy; or abstinence) and for at least a month after the study, and must have a negative serum pregnancy test at the Screening Visit. Females of childbearing potential are defined as women who are between menarche and 2 years post-menopause and who are not surgically sterilized. Males and Female subjects who are not sexually active, and who agree to be abstinent throughout the study, will not be required to use birth control.
Key exclusion criteria (18 listed)
- Subject has any psychiatric condition (e.g., schizophrenia or personality disorder as diagnosed by DSM-V) or clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by the investigator using medical history, physical examination, neurological examination, laboratory tests, and electrocardiograms. Common diseases such as mild hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C <6.5%), etc, are allowed per the investigator's judgment as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks before randomization and subsequently throughout the study. If there are any concerns about the suitability of the subject's medical or surgical condition, the investigator should review the subject's history with the medical monitor.
- Subject has a known or suspected human immune deficiency virus positive status or has diseases such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
- Subject has a history of an allergy or sensitivity to B-complex vitamins.
- Subject has a history of intellectual disability or a history or suspicion of autism spectrum disorder.
- Subject has a current clinically significant Axis I diagnosis (other than ADHD) according to the K-SADS-PL or has a lifetime history of bipolar disorder or psychosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Metadoxine extended releaseAlso: MDXMG01CI | Drug | MDX (metadoxine extended release) |
| PlaceboAlso: Sugar pillInactive drug | Drug | placebo |
Primary outcome
Safety and Tolerability
Time frame: Up to 6 weeks
Frequency of treatment emergent adverse events (AEs). Frequency of subjects who withdrew early from the study due to AE.
2 secondary outcomes
Efficacy
Time frame: Up to 5 weeks
PK
Time frame: Up to 5 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2015.
Related trials for ADHD, Predominantly Inattentive Type
RecruitingPhase 2
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Neurodevelopmental Disorders, Autism
Recruiting
A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care
ADHD, ADHD - Combined Type
Recruiting
NeuroTrainer Cognitive Training For Academic Focus
ADHD - Combined Type, ADHD Predominantly Inattentive Type
Not yet recruiting
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
Attention Deficit Disorder, Attention Deficit Disorder (ADD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iris Manor, MD principal investigator
ADHD Unit, Geha Medical Center, Petah Tikva, Israel
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Metadoxine extended release in people with ADHD, Predominantly Inattentive Type, run by Alcobra Ltd. at 6 sites in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability (time frame: Up to 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2015.